Amgen (AMGN) Q3 2026 (Tue Nov 3 2026 after close) — total revenue <meta name="viewport" content="width=device-width, initial-scale=1.0" />0.365B (+8% Y/Y) tops ~<meta name="viewport" content="width=device-width, initial-scale=1.0" />0.07B est; product sales $9.883B (+8%); Repatha <meta name="viewport" content="width=device-width, initial-scale=1.0" />.085B (+37%), EVENITY $751M (+39%), Tezspire $538M (+43%), Imdelltra $406M (+128%), Uplizna $451M (+191%), Pavblu $300M (+41%), Krystexxa $419M (+31%), Blincyto $496M (+27%), Vectibix $335M (+18%), Enbrel $611M (+5%); Prolia -45% to $632M and Xgeva -47% to $288M as biosimilars hit both; Otezla -18%, Tepezza -6%, Kyprolis -8%; GAAP diluted EPS $7.08 (+19%) vs non-GAAP $6.45 (+14%) vs ~$5.78 est; free cash flow $3.654B (vs $4.248B Y/Y) hit by $587M capex; FY26 guidance RAISED — revenues $38.9–$39.7B, non-GAAP diluted EPS $22.90–$23.70; capex ~$2.6B; buyback not to exceed $3.0B

0.365B (+8% Y/Y) tops ~0.07B est; product sales $9.883B (+8%); Repatha .085B (+37%), EVENITY $751M (+39%), Tezspire $538M (+43%), Imdelltra $406M (+128%), Uplizna $451M (+191%), Pavblu $300M (+41%), Krystexxa $419M (+31%), Blincyto $496M (+27%), Vectibix $335M (+18%), Enbrel $611M (+5%); Prolia -45% to $632M and Xgeva -47% to $288M as biosimilars hit both; Otezla -18%, Tepezza -6%, Kyprolis -8%; GAAP diluted EPS $7.08 (+19%) vs non-GAAP $6.45 (+14%) vs ~$5.78 est; free cash flow $3.654B (vs $4.248B Y/Y) hit by $587M capex; FY26 guidance RAISED — revenues $38.9–$39.7B, non-GAAP diluted EPS $22.90–$23.70; capex ~$2.6B; buyback not to exceed $3.0B" /> 0.365B (+8% Y/Y) tops ~0.07B est; product sales $9.883B (+8%); Repatha .085B (+37%), EVENITY $751M (+39%), Tezspire $538M (+43%), Imdelltra $406M (+128%), Uplizna $451M (+191%), Pavblu $300M (+41%), Krystexxa $419M (+31%), Blincyto $496M (+27%), Vectibix $335M (+18%), Enbrel $611M (+5%); Prolia -45% to $632M and Xgeva -47% to $288M as biosimilars hit both; Otezla -18%, Tepezza -6%, Kyprolis -8%; GAAP diluted EPS $7.08 (+19%) vs non-GAAP $6.45 (+14%) vs ~$5.78 est; free cash flow $3.654B (vs $4.248B Y/Y) hit by $587M capex; FY26 guidance RAISED — revenues $38.9–$39.7B, non-GAAP diluted EPS $22.90–$23.70; capex ~$2.6B; buyback not to exceed $3.0B" />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.